Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fast Track is an FDA process designed to facilitate development and expedite review of drugs to treat serious conditions and address unmet medical needs.
'The FDA's decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people living with celiac disease,' said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. 'Teva is driven by a commitment to innovation and this latest achievement gets us one step closer to providing promising, innovative treatment options for patients with chronic autoimmune diseases like celiac disease.'
TEV-53408 is an antibody designed to inhibit the activity of the cytokine, interleukin-15 (IL-15), to prevent intestinal damage and associated symptoms in individuals with celiac disease. This potential treatment is a testament to the growing strength of Teva's innovative pipeline and dedication to advancing treatments for immunological conditions, including celiac disease, which affects approximately 1% of the global population.1-3
About TEV-53408
TEV-53408 is an investigational monoclonal antibody that inhibits interleukin-15 (IL-15), which aims to reduce the immune response to gluten that causes intestinal inflammation and damage in individuals with celiac disease. A Phase 2a study investigating the efficacy and safety of anti-IL-15 in adults with celiac disease is ongoing (
NCT06807463
).
About Celiac Disease
Celiac disease is a chronic autoimmune disorder triggered by gluten, affecting the small intestine and leading to a range of symptoms. It can significantly impact an individual's quality of life, and diagnosis can be challenging. A strict, lifelong gluten-free diet is the only current treatment and even if adhering to a gluten-free diet, a significant proportion of patients still experience debilitating symptoms. In addition, trace amounts of gluten - especially through accidental or inadvertent ingestion - can cause severe reactions. Teva is dedicated to developing innovative medicines for immunological diseases, including celiac disease, with the goal of providing better health for people suffering from celiac disease worldwide.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit
www.tevapharm.com
.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to achieve expected results from investments in our product pipeline including to successfully develop and commercialize our anti-IL 15 (TEV-53408) asset for the treatment of people with celiac disease on a gluten-free diet; the risk that we will incur significant costs in connection with the development of anti-IL 15 (TEV-53408), which may exceed any revenue generated by anti-IL 15 (TEV-53408); risks that regulatory approvals and other requirements may delay the development and commercialization of our anti-IL 15 (TEV-53408); our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors and 'Forward Looking Statements.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
References
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
FDA warning: Don't eat these potentially radioactive shrimp sold at Walmart
You might want to think twice about buying this brand of shrimp next time you're shopping at Walmart. The U.S. Food and Drug Administration issued a warning to consumers about eating, selling or serving select brands of Great Value frozen raw shrimp due to contamination with a radioactive isotope. U.S. Customs and Border Protection alerted the FDA about the radioactive isotope, Cesium-137, after it was found in shipping containers at four U.S. seaports, according to the FDA. Here's what you need to know about the products that are affected and whether a recall will be imminent. What contaminated shrimp is the FDA warning consumers about? The Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp in 2-pound bags distributed by Indonesia's BMS Foods tested positive for the contamination. The FDA is recommending a recall on certain BMS shrimp products even if they did not test positive. While a recall hasn't been conducted yet, the FDA is working with distributors and retailers 'to recommend' a recall. The following products are affected: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027 The products were sold in Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. What should people do if they have the contaminated raw shrimp? The FDA is advising people who might have raw, frozen shrimp in their freezers from Walmart that matches the descriptions to not cook or consume them. Instead, the agency is asking customers, distributors and retailers to throw the shrimp away. The FDA also says, 'If you suspect you have been exposed to elevated levels of cesium, talk to your healthcare provider.' Consuming food or water contaminated with Cs-137 in low doses over an extended period of time can create an elevated risk of cancer due to a breakdown in DNA in the body's living cells, according to the FDA. Our journalism needs your support. Please subscribe today to Katherine Rodriguez can be reached at krodriguez@ Have a tip? Tell us at Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
FDA Pushes Back Eylea HD Review; Regeneron Still Gains
This article first appeared on GuruFocus. Regeneron (NASDAQ:REGN) picked up gains Tuesday after announcing that the FDA pushed back decision timelines for two key reviews of its high-dose Eylea (aflibercept) injection. The new action dates fall in the fourth quarter of 2025, covering a prior-approval supplement for a prefilled syringe and a label expansion filing to treat macular edema after retinal vein occlusion (RVO). Warning! GuruFocus has detected 3 Warning Signs with REGN. The company is also seeking to expand Eylea HD's dosing schedule to every 4 weeks across approved uses a shift from the current 816 week regimen for patients with wet AMD and diabetic macular edema. The extension stems from additional information submitted after an FDA inspection at Catalent Indiana LLC, the third-party manufacturer recently acquired by Novo Nordisk (NVO). The FDA classified the new submission as a major amendment, automatically extending review timelines. Novo Nordisk provided a detailed response earlier this month in an effort to address the agency's concerns. For now, Eylea HD remains available via vial administration, but the delay tempers near-term expectations around label expansion and convenience upgrades. Still, investors seem encouraged, with shares moving higher on confidence the regulator will complete its review later this year. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
3 hours ago
- The Hill
Walmart recalls frozen shrimp over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
